Associated Papers
Stoichiometric transport of estrone 3-sulfate among genetic variants of OATP1A2 and OATP2B1 and structural analysis by molecular dynamics simulation: Impairment of gating mechanism in the unstable inward-open conformation of OATP2B1 (Asp215Val) significantly suppress the transport activity.
Akiyoshi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Impact of Complex Genetic and Drug-Drug Interactions on Tamoxifen Metabolism and Efficacy.
Saad I et al.
Journal of Personalized Medicine, 2025
In vitro characterization of SLCO2B1 genetic variants.
Sinokki A et al.
Journal of Pharmaceutical Sciences, 2025
Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot study.
Hoste E et al.
British Journal of Pharmacology, 2025
Single-cell exome sequencing reveals polyclonal seeding and TRPS1 mutations in colon cancer metastasis.
Cai J et al.
Signal Transduction and Targeted Therapy, 2024
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study.
Lauritzen T et al.
Atherosclerosis Plus, 2024
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism.
Cramer EY et al.
Pharmacogenomics, 2023
Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines.
Hoste E et al.
Therapeutic Drug Monitoring, 2023
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
Keller DN et al.
Pharmacogenetics and Genomics, 2023
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
Nies AT et al.
Pharmacology & Therapeutics, 2022
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K et al.
Drug Metabolism and Pharmacokinetics, 2022
Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response.
Stillemans G et al.
Clinical and Translational Science, 2022
Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers.
Zeng W et al.
Frontiers in Nutrition, 2022
Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1).
Hussner J et al.
Drug Metabolism and Pharmacokinetics, 2021
Prostate Cancer Mortality Associated with Aggregate Polymorphisms in Androgen-Regulating Genes: The Atherosclerosis Risk in the Communities (ARIC) Study.
Prizment AE et al.
Cancers, 2021
Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer.
Shiota M et al.
Jma Journal, 2021
Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates.
Medwid S et al.
Frontiers in Pharmacology, 2021
Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers.
Lee SW et al.
The Pharmacogenomics Journal, 2020
Functional Characterization Reveals the Significance of Rare Coding Variations in Human Organic Anion Transporting Polypeptide 2B1 (SLCO2B1).
Yang J et al.
Molecular Pharmaceutics, 2020
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions.
Calderon-Ospina CA et al.
Pharmacogenomics and Personalized Medicine, 2020
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.
Turner RM et al.
Journal of Clinical Medicine, 2019
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.
Medwid S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2019
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children.
Li Q et al.
Drug Design, Development and Therapy, 2019
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW et al.
Clinical Pharmacology and Therapeutics, 2018
Update of green tea interactions with cardiovascular drugs and putative mechanisms.
Werba JP et al.
Journal of Food and Drug Analysis, 2018
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Sortica VA et al.
Pharmacogenomics, 2017
The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE et al.
Basic & Clinical Pharmacology & Toxicology, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.
Thompson MD et al.
Frontiers in Pharmacology, 2016
Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S et al.
Environmental Toxicology and Pharmacology, 2015
The Regulation of Steroid Action by Sulfation and Desulfation.
Mueller JW et al.
Endocrine Reviews, 2015
Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.
Ortega VE et al.
Pharmacogenomics and Personalized Medicine, 2015
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
Meyer zu Schwabedissen HE et al.
Bmc Research Notes, 2014
SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
Bui HT et al.
Cancer Investigation, 2014
Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N et al.
Prostate Cancer and Prostatic Diseases, 2013
Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
Kim KA et al.
Journal of Clinical Pharmacology, 2013
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK et al.
Circulation. Cardiovascular Genetics, 2013
SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.
Kim KA et al.
Molecular Biology Reports, 2013